Table of Content

1. Market Introduction and Scope
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. Executive Insights and Key Takeaways
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Cancer Type
2.4. Snippet by Treatment Type
2.5. Snippet by Route of Administration
2.6. Snippet by Region
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Advancements in Targeted Therapies
3.1.1.2. Expanding Clinical Trials and Research Investment
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Side Effects and Safety Concerns
3.1.2.2. High Treatment Costs
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Advancements in Treatment Options
3.1.3.2. XX
3.1.4. Impact Analysis
4. Strategic Insights and Industry Outlook
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. Gastric Cancer Treatment Market, By Cancer Type
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
5.1.2. Market Attractiveness Index, By Cancer Type
5.2. Non-Cardia (Distal) Stomach Cancer*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Proximal Stomach Cancer
5.4. Diffuse Stomach Cancer
5.5. Lymphomas
5.6. Gastrointestinal Stromal Tumors
5.7. Carcinoid Tumors
5.8. Adenocarcinoma
5.9. Others
6. Gastric Cancer Treatment Market, By Treatment Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Chemotherapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Capecitabine
6.2.4. Cisplatin
6.2.5. Docetaxel
6.2.6. Doxorubicin
6.2.7. Epirubicin?
6.2.8. Fluorouracil (5-FU)
6.2.9. Irinotecan
6.2.10. Leucovorin
6.2.11. Oxaliplatin
6.2.12. Paclitaxel
6.2.13. Others
6.3. Radiation Therapy
6.4. Targeted Therapy
6.4.1. Ramucirumab
6.4.2. Regorafenib
6.4.3. Trastuzumab
6.4.4. Zolbetuximab
6.4.5. Others
6.5. Immunotherapy
6.5.1. Nivolumab
6.5.2. Pembrolizumab
6.6. Surgery
6.6.1. Gastrectomy
6.6.2. Gastrojejunostomy
6.6.3. Others
6.7. Others
7. Gastric Cancer Treatment Market, By Route of Administration
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Injectable*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Oral
8. Gastric Cancer Treatment Market, By Regional Market Analysis and Growth Opportunities
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. UK
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. China
8.4.6.2. India
8.4.6.3. Japan
8.4.6.4. South Korea
8.4.6.5. Rest of Asia-Pacific
8.5. South America
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. Brazil
8.5.6.2. Argentina
8.5.6.3. Rest of South America
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9. Competitive Landscape and Market Positioning
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. Company Profiles
10.1. Merck & Co., Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue’s
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. Eli Lilly and Company
10.3. Genentech USA, Inc.
10.4. Pfizer Inc.
10.5. Astellas Pharma Inc.
10.6. Bristol-Myers Squibb Company
10.7. Blueprint Medicines Corporation
10.8. Daiichi Sankyo, Inc.
10.9. BeiGene, Ltd.
10.10. Ipsen Biopharmaceuticals Inc.
10.11. Taiho Oncology, Inc.
10.12. Deciphera Pharmaceuticals, LLC.
LIST NOT EXHAUSTIVE
11. Assumptions and Research Methodology
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. Appendix
12.1. About Us and Services
12.2. Contact Us